SPL 0.00% 9.7¢ starpharma holdings limited

Ann: DEP irinotecan outperforms in pancreatic cancer model, page-21

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,279 Posts.
    lightbulb Created with Sketch. 333
    What we need now is for a major media outlet to get hold of this news and run an article speaking to the fact that the DEP technology is continuing to record amazing results in both pre-clin and clinical trials in combination with multiple cancer fighting drugs and has now been patented by a major worldwide pharma.

    Headlines in major papers would do our SP no harm....
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.